Clinical Trials on Low/Intermediate Risk-1 MDS in India

Total 3 results

FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
All India Institute of Medical Sciences, New Delhi

Unknown

Sleep Quality in Pregnancy and Its Impact on Pregnancy Outcomes

Obstructive Sleep Apnea | Infant, Very Low Birth Weight | Pregnancy Induced Hypertension | High-Risk Pregnancy | Restless Leg Syndrome

India
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya

3

Subscribe